Inclusion Criteria:  The subject must meet all of the following criteria:  18-65 years old; Relapsed or refractory T-NHLs, including peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), ALK-positive ALCL, ALK-negative Image result for anaplastic large cell lymphoma (ALCL), enteropathy-related T-cell lymphoma, hepatosplenic T-cell lymphoma, etc.; Previously received ≥2 lines of treatment without a complete response; Immunohistochemical detection of tumor cells CD147 positive; ECOG score 0-2; The collection of mononuclear cells can be performed upon the judgment of the researcher; No contraindications for allogeneic hematopoietic stem cell transplantation (AlloHCT); Have donors for AlloHCT; Agree for sequential treatment of AlloHCT;  Without serious organ dysfunction in 2 weeks before CAR-T infusion:  Heart: without arrhythmia, LVEF≥50%, and without pericardial effusion; without heart failure (NYHA class III or IV) within12 months before CAR-T infusion; without myocardial infarction within 12 months before CAR-T infusion; without long-QT syndrome or secondary QT interval prolongation; Liver: ALT<2 times the upper limit of normal (ULN) and TBIL<1.5 times ULN, without active hepatitis; APTT and PT<1.5 times ULN; Kidney: Serum creatinine <1.5 mg/dl; or if the serum creatinine exceeds the upper limit, eGFR (CKD-EPI formula) needs to be > 50 ml/min; Fingertip blood oxygen saturation ≥ 92%. Estimated survival ≥ 3 months; Sexually active patients must be willing to use an effective method of birth control during the study period and within 6 months after the study ending, and male partners should use condoms; The patient is willing to join this clinical trial and sign an informed consent.  Exclusion Criteria:  Anyone who has one or more of the following:  A history of other malignancies with a disease-free period < 5 years (except for cured basal cell carcinoma of the skin, cured cervical carcinoma in situ, and gastrointestinal tumors proven to be cured by endoscopic mucosal resection); Those who have received allogeneic hematopoietic stem cell transplantation or organ transplantation; Patients with bone marrow involvement; Those who are allergic to the biological agents in CAR-T cell product ; Pregnant or breastfeeding; Active bacterial, fungal or viral infection; Receiving systemic hormone therapy 1 week before participating in the clinical trial; Have received other gene therapy before; HBV or HCV infection or carrier is defined as: HBsAg positive or HBV-DNA positive; anti-HCV positive and HCV-RNA positive; Active HIV infection; Clinical diagnosis of virus infection or uncontrolled virus activation, including cytomegalovirus (CMV), adenovirus (ADV), BK virus or human herpesvirus 6 (HHV-6), etc.; Central nervous system lymphoma (CNSL) is defined as the presence of ≥5 tumor cells/ ul in cerebrospinal fluid (CSF) or MRI suggested CNSL; any other CNS diseases, such as uncontrolled epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar disease or any autoimmune disease involving the central nervous system, or received treatment for central nervous system or brain metastasis (radiotherapy, surgery or other treatments); Imaging determined lung infection; Inappropriate to participate in the trial with investigators' decision.